Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Parno

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Thrombosis Research|February 1, 1985
Limitation of impedance plethysmography in assessing efficacy of dihydroergotamine-heparin prophylaxis of deep vein thrombosisF J DiSerio, J Parno, J M Singer
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|June 1, 1995
Comparison of the maximum tolerated dose (MTD) dermal response in three strains of mice following repeated exposure to acrylic acidJ E McLaughlin, J Parno, F M Garner, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasisY Poulin, M Ramon, L Rosoph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2019
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trialsA Blauvelt, H Sofen, K Papp, et al.
The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Thrombosis Research|February 1, 1985
Limitation of impedance plethysmography in assessing efficacy of dihydroergotamine-heparin prophylaxis of deep vein thrombosisF J DiSerio, J Parno, J M Singer
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|June 1, 1995
Comparison of the maximum tolerated dose (MTD) dermal response in three strains of mice following repeated exposure to acrylic acidJ E McLaughlin, J Parno, F M Garner, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasisY Poulin, M Ramon, L Rosoph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 14, 2019
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trialsA Blauvelt, H Sofen, K Papp, et al.
The Journal of Dermatological Treatment|May 1, 2020
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trialsK B Gordon, K Reich, J J Crowley, et al.
Pageof 1